Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Depreciation & Amortization (CF) (2016 - 2025)

Fate Therapeutics (FATE) has disclosed Depreciation & Amortization (CF) for 14 consecutive years, with $3.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Depreciation & Amortization (CF) fell 36.38% year-over-year to $3.1 million, compared with a TTM value of $12.9 million through Dec 2025, down 31.97%, and an annual FY2025 reading of $12.9 million, down 31.97% over the prior year.
  • Depreciation & Amortization (CF) was $3.1 million for Q4 2025 at Fate Therapeutics, down from $3.2 million in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $4.9 million in Q4 2023 and bottomed at $959000.0 in Q1 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $3.5 million, with a median of $3.3 million recorded in 2025.
  • The sharpest move saw Depreciation & Amortization (CF) skyrocketed 187.9% in 2022, then plummeted 36.38% in 2025.
  • Year by year, Depreciation & Amortization (CF) stood at $2.3 million in 2021, then skyrocketed by 116.49% to $4.9 million in 2022, then grew by 0.39% to $4.9 million in 2023, then dropped by 1.84% to $4.8 million in 2024, then tumbled by 36.38% to $3.1 million in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for FATE at $3.1 million in Q4 2025, $3.2 million in Q3 2025, and $3.3 million in Q2 2025.